PCG Advisory

03/26/2026

Today we shared our Corporate Update and Fourth Quarter and Full-Year 2025 Financial Results.

"2025 was a defining year for Quoin as we transitioned from clinical stage to a company actively preparing for commercial readiness." — Michael Myers, CEO
Key highlights include:
• Closed a private placement financing of up to $104.5 million, strengthening our balance sheet and funding operations into 2027
• Orphan Drug Designations in the U.S. and Europe
• Fast Track Designation in the U.S. for QRX003 in Netherton Syndrome
• Continued progress toward expedited regulatory pathways in Japan and Saudi Arabia
• Expansion of our pediatric Netherton Syndrome study to 7 actively treated children, the largest cohort of this age group ever studied
• Continued advancement of our Peeling Skin Syndrome and topical rapamycin programs, including expansion of the Peeling Skin Syndrome study to 6 subjects
• NETHERTON NOW reaching nearly 2 million video views and 24 million global impressions

As we move into 2026, we remain focused on advancing QRX003 and expanding our pipeline on behalf of patients and families living with rare and orphan diseases. We look forward to sharing further progress throughout the year.
https://investors.quoinpharma.com/news-releases/news-release-details/quoin-pharmaceuticals-provides-corporate-update-and-reports-0

03/25/2026

An important regulatory milestone for Quoin Pharmaceuticals.
Following a constructive Type C meeting with the U.S. Food and Drug Administration, we are advancing our Phase 3 plans for QRX003 in Netherton Syndrome, a rare and severe genetic skin disease with no approved treatments.

The FDA indicated that a single Phase 3 study may be sufficient to support U.S. marketing approval and supported consideration of clinical trial designs that may better align with this patient population.

This feedback provides increased clarity on the regulatory path forward and strengthens our confidence as we advance our pivotal program. Quoin remains on track to initiate Phase 3 and complete patient recruitment in 2026, with the potential to file an NDA in 2027.

Today’s update marks an important step forward in our mission to develop a potential treatment for patients and families living with Netherton Syndrome who have waited so long.
https://investors.quoinpharma.com/news-releases/news-release-details/quoin-pharmaceuticals-provides-clinical-and-regulatory-update

03/24/2026

SKYX Platforms Announces Corporate Update Call

SKYX Announces Corporate Update Call

03/24/2026

AtlasClear Announces Commencement of Dawson James Clearing Operation

AtlasClear Holdings, Inc. (NYSE American: ATCH) (“AtlasClear” or the “Company”), a financial services company building modern clearing, custody, and trading infrastructure, today announced that Dawson James Securities, Inc. has commenced clearing operations through Wilson-Davis & Co., Inc., ...

03/16/2026

Auddia Highlights LT350 as Resilient AI Infrastructure as Iran War Exposes Vulnerabilities in Centralized Hyperscale Datacenters

Auddia Inc. (NASDAQ: AUUD) (“Auddia” or the “Company”), today highlighted the strategic relevance of its LT350 distributed AI infrastructure platform following new institutional research indicating that hyperscale AI datacenters have become military targets in the Iran war and are now consid...

03/11/2026

SKYX Platforms it will Supply its Technologies to Enable a New Contemporary Apartment Community in New York as it Continues to Grow its Market Pe*******on

SKYX Announces it will Supply its Technologies to Enable a New Contemporary Apartment Community in New York as it Continues to Grow its Market Pe*******on

03/11/2026

AtlasClear Holdings to Attend the 38th Annual ROTH Conference

AtlasClear Holdings, Inc. (NYSE American: ATCH) (“AtlasClear” or the “Company”), a financial services company building modern clearing, custody, and trading infrastructure, today announced that it will be participating in the 38th Annual ROTH Conference on March 22–24, 2026.

03/11/2026

Auddia Announces Non-binding LOI with NYSE Listed Medical REIT to Deploy LT350 Solar-Integrated AI Micro-Datacenter Canopy

(“Auddia” or the “Company”), today announced that LT350 has signed a non-binding Letter of Intent (“LOI”) with a NYSE listed medical REIT (the “Medical REIT”) to host LT350’s first pilot installation expected to be at a hospital property in the Dallas Fort Worth MSA.

02/26/2026

Auddia $AUUD Highlights LT350 Business as Core AI Infrastructure Asset in Proposed Merger

BOULDER, Colo., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Auddia Inc. (NASDAQ: AUUD) (“Auddia” or the “Company”), today announced a comprehensive strategic overview of LT350, a distributed AI compute business engineered to address two of the most urgent constraints in the AI infrastructure market:

02/19/2026

SKYX Platforms $SKYX Provides Corporate Update including New Product Launches, NVIDIA Collaboration, and $29 Million in Recent Investments from Fundamental Institutions

SKYX Provides Corporate Update including New Product Launches, NVIDIA Collaboration, and $29 Million in Recent Investments from Fundamental Institutions

02/11/2026

SKYX Platforms Announces Launch at Walmart, U.S. Leading Retailer, of its Ceiling Plug & Play SKYFAN & TURBO HEATER

SKYX Announces Launch at Walmart, U.S. Leading Retailer, of its Ceiling Plug & Play SKYFAN & TURBO HEATER

01/27/2026

SKYX Announces Closing of $25 Million in Funding via Offering of Common Stock at $2.50 per share from One Fundamental Institutional Investor

SKYX Announces Closing of $25 Million in Funding via Offering of Common Stock at $2.50 per share from One Fundamental Institutional Investor